Phase I Dose-Escalation Trial Combining Olaparib and Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
This study established the MTD and recommended a phase II dose of olaparib at 200 mg twice daily with concurrent low-dose TRT, and the combination seemed safe without unexpected toxicities.
Authors
- Robert Michael Daly (ORCID: https://orcid.org/0000-0001-6573-7650)
- Michael David Offin (ORCID: https://orcid.org/0000-0002-7959-3018)
- Benjamin H. Lok (ORCID: https://orcid.org/0000-0002-3675-8847)
- Michelle S. Ginsberg (ORCID: https://orcid.org/0000-0003-0304-110X)
- Daphna Y. Gelblum (ORCID: https://orcid.org/0000-0001-7211-6246)
- Helena A. Yu (ORCID: https://orcid.org/0000-0002-0377-9510)
- Rupesh Kotecha (ORCID: https://orcid.org/0000-0001-6927-0402)
- Narek Shaverdian (ORCID: https://orcid.org/0000-0002-0294-8749)
- Abraham J. Wu (ORCID: https://orcid.org/0000-0002-2597-7091)
- Vanessa J. Ng (ORCID: https://orcid.org/0009-0001-0690-1681)
- Jacob Y. Shin (ORCID: https://orcid.org/0000-0003-1558-3731)
- Quincey LaPlant (ORCID: https://orcid.org/0000-0002-4856-4433)
- Charles M. Rudin (ORCID: https://orcid.org/0000-0001-5204-3465)
- Andreas Rimner (ORCID: https://orcid.org/0000-0002-1214-3856)
- Charles B. Simone (ORCID: https://orcid.org/0000-0002-0867-3694)
- Annemarie Fernandes Shepherd (ORCID: https://orcid.org/0000-0002-4469-0889)
- Zhigang Zhang (ORCID: https://orcid.org/0000-0002-1556-7945)
- Ellen Yorke (ORCID: https://orcid.org/0000-0003-2604-3140)
- Alina Ionescu (ORCID: https://orcid.org/0009-0009-7923-9201)
Institutions
- Baptist Hospital of Miami (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Freiburg (DE)
- University of Washington (US)
- Princess Margaret Cancer Centre (CA)
- Baptist Health South Florida (US)
- New York Proton Center (US)
- Seattle University (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-4342
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00